🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

314 results for “cells” Clear

  1. Bone marrow derived stem cells

    Neuroscience Trials Australia

    Spinal Cord Injury

    phase 2 other active

    1 trial

  2. Bone marrow mesenchymal stem cells (low dose)

    Sun Yat-sen University

    Acute-On-Chronic Liver Failure

    phase 2 small molecule active

    1 trial

  3. Bone marrow mesenchymal stem cells autologous

    Lxo Ireland Designated Activity Company

    Multiple Sclerosis

    phase 2 other completed

    1 trial

  4. Bone marrow mononuclear cells

    Lxo Ireland Designated Activity Company

    Chronic Myocardial Ischemia

    phase 2 other completed

    1 trial

  5. Bronchial basal cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Bronchiectasis

    phase 2 mab active

    1 trial

  6. Bronchial basal cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Obstructive Pulmonary Disease

    phase 2 mab completed

    1 trial

  7. Busulfan Koanaa 6 mg/ml Konzentrat zur Herstellung einer Infusionslösung, GRANOCYTE 34 Millions UI/ml, poudre et solvant pour solution injectable / perfusion, Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene, Plerixafor Accord 20 mg/ml solution for injection

    Fondazione Telethon ETS

    transfusion-dependent beta-thalassemia

    phase 2 small molecule active

    1 trial

  8. CAP-1002 Allogeneic Cardiosphere-Derived Cells

    CAPRICOR THERAPEUTICS, INC.

    Myocardial Infarction

    phase 2 mab terminated

    1 trial

  9. CAR-BCMA T Cells

    The First People's Hospital of Lianyungang

    Multiple Myeloma

    phase 2 mab active

    1 trial

  10. CAR-T Cells

    The First People's Hospital of Lianyungang

    Lung Neoplasm Malignant

    phase 2 mab active

    1 trial

  11. CD123 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  12. CD123 targeted CAR-NK cells

    Chongqing Precision Biotech Co., Ltd

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial

  13. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Autoimmune Diseases

    phase 2 mab active

    1 trial

  14. CD19 CAR-T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia

    phase 2 mab active

    1 trial

  15. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials

  16. CD19 CAR-T cells and CD19 positive feeder T cells

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia in Remission

    phase 2 mab active

    1 trial

  17. CD19 and CD22 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia, B-cell

    phase 2 mab active

    2 trials

  18. CD19 and CD22 targeted prime CAR- T cells

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 2 mab active

    1 trial

  19. CD19 and CD22 targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    B-ALL

    phase 2 mab active

    1 trial

  20. CD19 or CD20 CAR T cells briging HSCT

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  21. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Solid Tumor

    phase 2 mab active

    1 trial

  22. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 2 mab active

    3 trials

  23. Columvi 10 mg concentrate for solution for infusion, Gazyvaro 1,000 mg concentrate for solution for infusion., Breyanzi 1.1-70 × 106 cells/mL / 1.1-70 × 106 cells/mL dispersion for infusion, YESCARTA 0.4 – 2 x 10e8 cells dispersion for infusion

    The George Institute

    relapsed/refractory Large B-Cell Lymphoma

    phase 2 small molecule active

    1 trial

  24. Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.

    Lxo Ireland Designated Activity Company

    Graft Versus Host Disease

    phase 2 other completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources